Ascelia Pharma AB (OSTO:ACE) Interest Expense: kr-3.52 Mil (TTM As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
29 GF Score
Price kr2.91
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Interest Expense?

Ascelia Pharma AB OSTO:ACE -1.69% 29 Interest Expense is kr-3.52 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ascelia Pharma AB's interest expense for the three months ended in Mar. 2026 was kr -0.25 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr-3.52 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ascelia Pharma AB's Operating Income for the three months ended in Mar. 2026 was kr -17.17 Mil. Ascelia Pharma AB's Interest Expense for the three months ended in Mar. 2026 was kr -0.25 Mil. Ascelia Pharma AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ascelia Pharma AB  (OSTO:ACE) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ascelia Pharma AB's Interest Expense for the three months ended in Mar. 2026 was kr-0.25 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr-17.17 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr0.00 Mil.

Ascelia Pharma AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Ascelia Pharma AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Ascelia Pharma AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Interest Expense Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only -0.08 -0.05 0.00 -3.71 -1.70

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.24 -2.03 -0.90 -0.34 -0.25
OSTO:ACE
29GF Score
Ascelia Pharma AB OSTO:ACE
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-3.52 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Interest Expense of kr-3.52 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Interest Expense too high?
Ascelia Pharma AB's current Interest Expense is kr-3.52 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Interest Expense compare to VRTX and REGN?
Ascelia Pharma AB's Interest Expense of kr-3.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Interest Expense is kr-3.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Interest Expense of kr-3.52 Mil. The current Interest Expense is kr-3.52 Mil. Ascelia Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Interest Expense is kr-3.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score

Get the complete analysis for OSTO:ACE

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.91
Price